Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis

TORONTO – A highly anticipated phase III trial of an anti-tau drug has posted negative topline results, conferring no cognitive or functional benefits when given in conjunction with standard-of-care...

Source: Clinical Neurology News - July 27, 2016 Category: Neurology Source Type: news